Summary of clinical results

AVENE
av_cl_comedomed

Tolerance and efficacy of CLEANANCE COMEDOMED+ Intensive anti-blemish care as a maintenance treatment for facial acne

Tolerance and efficacy of CLEANANCE COMEDOMED+ Intensive anti-blemish care in teenagers and adults as a maintenance treatment for facial acne, under dermatological control
Real-life international cohort study with 12-month follow-up

Population

54 subjects aged 12 to 35 with mild to moderate facial acne (GEA score 1 to 3) and oily skin

Application of CLEANANCE COMEDOMED+ Intensive anti-blemish care

  • 2 applications a day on the face for 1 year

Evaluation criteria

  • Acne severity (GEA score = Global Evaluation of Acne)
  • Lesion count (Lucky method)
  • Acne relapse rate (GEA score ≥3 requiring the introduction of anti-acne treatment)
  • Quality of life questionnaire (Cardiff Acne Disability Index - CADI)
  • Skin tolerance

Results

  • No acne relapse for 90% of subjectsat 6 months and 85% of subjects at 1 year
  • Statistically significant improvement in acne severity score at 6 and 12 months (p<0.001, versus inclusion)
COMEDOMED+ - GEA

Change in acne severity score (GEA) over 12 months

** p= Statistically Highly Significant (p<0.001, versus inclusion)

 

  • Highly significant improvement in the number of inflammatory and non-inflammatory lesions, with effect maintained at 1 year: -53.9% and -61.3% respectively (p<0.0001)
COMEDOMED+ - Inflammatory and non-inflammatory lesions

Evolution of the number of inflammatory and non-inflammatory lesions (lesion count) over 12 months

** p= Statistically Highly Significant (p<0.001, versus inclusion)

 

  • Highly significant reduction in CADI score after 1 year: -53.7% (p<0.001, versus inclusion)

  • Excellent cutaneous tolerance for 98% of subjects

Conclusion

CLEANANCE COMEDOMED+ Soin intensif anti-imperfections applied twice daily as a maintenance treatment for 1 year improves acne severity and limits recurrences

No acne relapse for 90% of subjects at 6 months and 85% of subjects at 1 year

Excellent skin tolerance

More summaries of clinical results